IT NewsBusiness ToolsService & Support
Ekaterina Alexandrova | 07/27/2020
The ChemRar Research Institute has created a platform for the development of innovative drugs against the new coronavirus infection.
The platform includes a specially created library of potentially active antiviral (SARS-CoV-2) small molecules, a set of methods, including virtual screening, and test systems that allow
to detect the activity of invitro compounds in a high-performance format (up to 5000 compounds per day) with subsequent invivalence of the leading compounds. The platform provides the development of a ready
preclinical candidate from scratch in just a few months. The advantages of the service are the completeness and speed of work.
The platform includes: a library of potential antiviral molecules (13,000 compounds), CPE testing with the SARS-CoV-2 virus, protease tests (3CL and PLpro), polymerase tests (RdRp),
spike study (ACE2-S1), study of antiviral activity of a future candidate on hamsters, pharmacokinetic studies, medico-chemical optimization services.
ChemRar Group of Companies invites potential partners to use the platform and invites international companies to cooperate in finding solutions for the treatment of COVID-19.
medicine, services for business, platforms
Center for High Technologies “ChemRar”